Macquarie Group
ACHV icon

Macquarie Group’s Achieve Life Sciences ACHV Stock Holding History

Macquarie Group’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,047
Closed -$5 – 1891
2024
Q1 		$5 Buy
+1,047
New +$4.65K ﹤0.01% 1779

Other funds holding ACHV

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Macquarie Group's ACHV Position: Q2 2024 in Review

Macquarie Group sold out of Achieve Life Sciences (ACHV) in Q2 2024, closing a stake of 1,047 shares — an estimated $5 sold.

Macquarie Group first reported a position in ACHV in Q1 2024 and held it in 1 quarter. The position peaked at $5 in Q1 2024. 56 funds tracked by Wall St. Rank hold ACHV as of Q2 2024.

  • Macquarie Group reported no remaining Achieve Life Sciences position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 1,047 Achieve Life Sciences shares in Q2 2024, an estimated $5.
  • Macquarie Group first reported a position in Achieve Life Sciences in Q1 2024 and held it in 1 quarter.
  • Macquarie Group's Achieve Life Sciences position peaked at $5 in Q1 2024.
  • 56 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.